We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

TG Therapeutics stock popped Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...

Most readers would already be aware that TG Therapeutics' (NASDAQ:TGTX) stock increased significantly by 49% over ...

During the last three months, 4 analysts shared their evaluations of TG Therapeutics TGTX, revealing diverse outlooks from ...

TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...

TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $23.19 which represents a slight increase of $0.12 or 0.52% from the prior close of $23.07. The stock opened at $22 ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Boston Scientific (BSX – Research Report) with bullish ...

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II ...

As of the latest trading close, TGTX, a Healthcare sector stock, is trading -3.15% below its 52-week high but remains 285.29% above its 52-week low. The Average True Range (ATR) (14 days) of 1.42 ...

TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.